Drug-induced photosensitivity.
(1) Photosensitivity reactions are cutaneous disorders due to exposure to ultraviolet (UV) radiation of natural or artificial origin. They occur or are more prevalent on unprotected skin. The main clinical manifestations are burns, eczema-like rash, urticaria, pigmentation, or onycholysis; (2) Many drugs increase cutaneous sensitivity to UV, sometimes for therapeutic purposes, but it is generally an unwanted effect.
D000622:Aminolevulinic Acid / Q000009:adverse effects* / Q000031:analogs & derivatives*; D000638:Amiodarone / Q000009:adverse effects*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002317:Cardiovascular Agents / Q000009:adverse effects*; D017454:Dermatitis, Photoallergic / Q000209:etiology*; D017484:Dermatitis, Phototoxic / Q000209:etiology*; D017323:Dihematoporphyrin Ether / Q000009:adverse effects*; D004232:Diuretics / Q000009:adverse effects*; D004318:Doxycycline / Q000009:adverse effects*; D004342:Drug Hypersensitivity; D064420:Drug-Related Side Effects and Adverse Reactions; D004485:Eczema / Q000139:chemically induced*; D011564:Furocoumarins / Q000009:adverse effects*; D006414:Hematoporphyrin Photoradiation / Q000009:adverse effects*; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects*; D054039:Onycholysis / Q000139:chemically induced*; D010778:Photochemotherapy / Q000009:adverse effects*; D010787:Photosensitivity Disorders / Q000139:chemically induced*; D017319:Photosensitizing Agents / Q000009:adverse effects*; D011166:Porphyrins / Q000009:adverse effects*; D011619:Psychotropic Drugs / Q000009:adverse effects*; D011804:Quinolines / Q000009:adverse effects*; D012867:Skin / Q000187:drug effects* / Q000528:radiation effects; D015595:Skin Aging; D012871:Skin Diseases / Q000139:chemically induced*; D012878:Skin Neoplasms / Q000139:chemically induced*; D012880:Skin Pigmentation; D013449:Sulfonamides / Q000009:adverse effects*; D013473:Sunscreening Agents / Q000627:therapeutic use; D013752:Tetracycline / Q000009:adverse effects*; D014466:Ultraviolet Rays / Q000009:adverse effects*; D014581:Urticaria / Q000139:chemically induced*; D000077362:Verteporfin
D000889:Anti-Arrhythmia Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002317:Cardiovascular Agents; D004232:Diuretics; D011564:Furocoumarins; D017319:Photosensitizing Agents; D011166:Porphyrins; D011619:Psychotropic Drugs; D011804:Quinolines; D013449:Sulfonamides; D013473:Sunscreening Agents; D000077362:Verteporfin; C475457:methyl 5-aminolevulinate; D000622:Aminolevulinic Acid; D017323:Dihematoporphyrin Ether; D013752:Tetracycline; D004318:Doxycycline; D000638:Amiodarone; D008727:Methotrexate